Cargando…
Development and characterization of novel anti‐C5 monoclonal antibodies capable of inhibiting complement in multiple species
Over the last decade there has been an explosion in complement therapies; one‐third of the drugs in the clinic or in development target C5 protein. Eculizumab, a monoclonal antibody (mAb) that binds C5 and blocks its cleavage by the convertase, is the current reference standard treatment for atypica...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620185/ https://www.ncbi.nlm.nih.gov/pubmed/31120547 http://dx.doi.org/10.1111/imm.13083 |